
|Videos|December 26, 2014
Dr. Gomella on Labeling Low-Risk Prostate Cancer
Author(s)Leonard G. Gomella, MD
Leonard Gomella, MD, urology specialist from Jefferson University, talks about the challenge of treating prostate cancer patients with a Gleason score of less than six.
Advertisement
Leonard Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, talks about the challenge of treating prostate cancer patients with a Gleason score of less than six.
Active surveillance is an appropriate treatment for the majority of those with Gleason six prostate cancer, but often the term ‘cancer’ makes patients feel like they need more aggressive treatment.
Overtreatment is a common problem, which may be solved by renaming the disease, says Gomella.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
5




































